The Pharmocogenomics of Warfarin

Warfarin, a coumarin anticoagulant, is used worldwide for the treatment and prevention of thromboembolic disease. Warfarin therapy, however, can be difficult to manage because of the drug’s narrow therapeutic index and the wide interindividual variability in patient response. It is now clear that...

Full description

Saved in:
Bibliographic Details
Published inMolecular interventions Vol. 6; no. 4; p. 223
Main Authors Allan E. Rettie, Guoying Tai
Format Journal Article
LanguageEnglish
Published American Society for Pharmacology and Experimental Therapeutics 01.08.2006
Online AccessGet full text

Cover

More Information
Summary:Warfarin, a coumarin anticoagulant, is used worldwide for the treatment and prevention of thromboembolic disease. Warfarin therapy, however, can be difficult to manage because of the drug’s narrow therapeutic index and the wide interindividual variability in patient response. It is now clear that genetic polymorphisms in genes influencing metabolism ( CYP2C9 ) and pharmacodynamic response ( VKORC1 ) are strongly associated with warfarin responsiveness. Optimal warfarin dosing in turn drives other positive anticoagulation–related outcomes. Therefore, a strong basic science argument is emerging for prospective genotyping of warfarin patients. Effective clinical translation would establish warfarin pharmacogenomics as a heuristic model for personalized medicine.
ISSN:1534-0384
1543-2548
DOI:10.1124/mi.6.4.8